REFERENCES
Alving BA, Barr CF, Johansen LE, Tang DB (1992) Comparison between a one-point dilute phospholipid APTT and the dilute Russell viper time for verification of lupus anticoagulants. Thromb Haemost 67: 672–678.
Beutler E, Grabowski GA (1995) Glucosylceramide lipidoses: Gaucher disease. In Scriver CR, Beaudet AL, Sly WS, Valle E, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 2641–2670.
Billett HH, Rizvi S, Sawitsky A (1996) Coagulation abnormalities in patients with GaucherÏs disease: e.ect of therapy. Am J Hematol 51: 234–236.
Charrow J, Esplin JA, Gribble J, et al (1998) Gaucher disease. Recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158: 1754–1760.
Hollak CEM, Levi M, Berends F, Aerts JMFG, van Oers MHJ (1997) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96: 470–476.
Love PE and Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and not-SLE disorders. Ann Intern Meds 112: 682–698.
Zimran A, Kay AC, Gelbart T, et al (1992) The natural history of adult type Gaucher disease: clinical, laboratory, radiologic and genetic features of 53 patients. Medicine 71: 337–353.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barone, R., Giuffrida, G., Musso, R. et al. Haemostatic abnormalities and lupus anticoagulant activity in patients with Gaucher disease type I. J Inherit Metab Dis 23, 387–390 (2000). https://doi.org/10.1023/A:1005655903139
Issue Date:
DOI: https://doi.org/10.1023/A:1005655903139